Doctors Note Logo

Published on: 11/9/2026

Atypical Cystic Fibrosis: Why Residual CFTR Mutations Can Delay Diagnosis Until Adulthood

Atypical cystic fibrosis occurs when "residual function" CFTR mutations allow partial chloride channel activity, producing milder, organ-limited symptoms such as recurrent sinusitis, bronchiectasis, pancreatitis, or male infertility instead of classic childhood failure to thrive. Because sweat chloride results are often borderline or normal and newborn screening panels miss many rare variants, diagnosis is frequently delayed into the 30s, 40s, or later, with patients misdiagnosed as having asthma, chronic bronchitis, or idiopathic pancreatitis for years. Several factors affect who gets diagnosed late and which tests actually confirm it, including expanded genetic sequencing, nasal potential difference testing, and genotype-phenotype variability; see below to understand more before assuming your symptoms are unrelated.

If you have had years of unexplained respiratory, sinus, or digestive problems, a few minutes spent clarifying your pattern of symptoms can help you ask the right questions and reach the right specialist sooner. Take a free, instant, online symptom check to better understand what may be driving your symptoms and what steps to consider next.

Last reviewed for medical accuracy: 11/09/2026

answer background

Concerned about your symptoms?

Explanation

Atypical Cystic Fibrosis: Why Residual CFTR Mutations Can Delay Diagnosis Until Adulthood

Cystic fibrosis is a genetic condition that affects the CFTR protein, which helps control the movement of salt and water across cell surfaces. When CFTR does not work properly, the body can produce unusually thick, sticky mucus. This can affect the lungs, sinuses, pancreas, intestines, liver, reproductive system, and sweat glands.

Many people think cystic fibrosis is always diagnosed in infancy or childhood. Newborn screening has made early diagnosis much more common, but some people are not identified until their teenage years or adulthood. This is more likely when they have an atypical, nonclassic, or milder form of cystic fibrosis caused by CFTR variants that retain some function.

The symptoms may be less obvious, tests may produce borderline results, and the condition can resemble more common illnesses. As a result, diagnosis may take time.

What does “residual CFTR function” mean?

The CFTR gene provides instructions for making the CFTR protein. A person with cystic fibrosis has disease-causing changes, known as variants or mutations, in both copies of the CFTR gene.

Not all CFTR variants affect the protein in the same way. Some prevent the protein from being made or transported to the cell surface. Others allow a smaller amount of working protein to reach the correct location. This remaining activity is called residual CFTR function.

In general, more residual function may lead to:

  • Less severe or slower-progressing lung disease
  • Fewer or milder digestive symptoms
  • A normal or borderline sweat chloride test
  • Pancreas function that remains normal
  • Symptoms limited mainly to one organ system
  • Diagnosis later in life

However, the relationship between a particular variant and a person’s symptoms is not always predictable. People with the same CFTR variants can have different health experiences because of other genes, infections, environmental exposures, access to treatment, and chance.

How atypical cystic fibrosis differs from classic disease

Classic cystic fibrosis often causes several recognizable features during childhood, such as persistent chest infections, poor growth, greasy stools, or a very high sweat chloride level. Atypical cystic fibrosis may involve only one or two features, and symptoms may be intermittent.

An adult with a milder form might have:

  • Repeated bronchitis, pneumonia, or sinus infections
  • A chronic cough with mucus
  • Bronchiectasis, which is permanent widening and scarring of the airways
  • Male infertility caused by congenital absence or blockage of the vas deferens
  • Recurrent pancreatitis
  • Unexplained digestive problems or difficulty maintaining weight
  • Salty-tasting skin or dehydration during heat, exercise, or illness
  • Nasal polyps or long-standing sinus disease
  • Abnormal liver tests in some cases

These symptoms are not specific to cystic fibrosis. Asthma, allergies, immune disorders, smoking-related lung disease, chronic infection, celiac disease, and other conditions can cause similar problems. That overlap is one reason an adult diagnosis may be delayed.

Why diagnosis can be difficult in adulthood

1. Newborn screening may not detect every case

Newborn screening is designed to identify babies at increased risk, not to diagnose every person with cystic fibrosis. Screening methods vary by region and commonly measure immunoreactive trypsinogen, followed by testing for selected CFTR variants or additional blood markers.

A person with a less common CFTR variant, a variant not included in the screening panel, or a borderline screening result may not be identified as a newborn. Some adults were also born before routine newborn screening became widely available.

2. Symptoms may appear gradually

A person with residual CFTR function may remain relatively well for years. Lung damage, recurrent sinus disease, fertility problems, or pancreatitis may be the first significant clue. Sometimes the diagnosis is considered only after a chest scan shows bronchiectasis or after a person has an unusual pattern of repeated infections.

3. Sweat testing may be inconclusive

The sweat chloride test is a central test for cystic fibrosis. It measures the amount of chloride, a component of salt, in sweat.

According to widely used clinical standards, a sweat chloride result of 60 mmol/L or higher supports a diagnosis when the clinical picture and genetic findings are consistent. A result below 30 mmol/L makes cystic fibrosis less likely, although it does not automatically rule out every CFTR-related condition. Results from 30 to 59 mmol/L are considered intermediate and usually require further assessment.

People with atypical cystic fibrosis may have sweat chloride results that are intermediate or occasionally within the usual range. Testing should be performed at an accredited center and may need to be repeated if the result is unclear.

4. Genetic testing may be incomplete

A basic CFTR test may look only for the most common variants. This can miss rare variants, large deletions, duplications, or changes in parts of the gene that are not included in a limited panel.

If suspicion remains, a cystic fibrosis specialist may recommend more comprehensive testing, such as full CFTR sequencing and deletion or duplication analysis. Genetic testing must be interpreted alongside symptoms, sweat testing, and other clinical findings. Finding one CFTR variant does not automatically mean a person has cystic fibrosis.

How doctors investigate suspected atypical cystic fibrosis

Evaluation usually begins with a detailed medical and family history. The doctor may ask about childhood respiratory infections, sinus disease, digestive symptoms, fertility, pancreatitis, and relatives with cystic fibrosis or unexplained lung disease.

Testing may include:

  • A properly performed sweat chloride test, often repeated
  • Comprehensive CFTR genetic testing
  • Lung function testing
  • Chest imaging, especially if bronchiectasis is suspected
  • Sputum testing for bacteria
  • Pancreatic function tests, such as fecal elastase
  • Testing for nutritional deficiencies or liver involvement
  • Semen analysis in men with possible obstructive infertility

Doctors may classify some cases as CFTR-related disorders rather than definite cystic fibrosis. Examples include congenital absence of the vas deferens, recurrent pancreatitis linked to CFTR variants, or bronchiectasis with CFTR dysfunction. The exact label matters because it guides monitoring and treatment, but the person’s symptoms and health needs remain the priority.

Treatment and long-term care

Treatment depends on the organs involved and the specific CFTR variants. A person with mild disease may not need every treatment used for classic cystic fibrosis, but regular specialist follow-up is still important.

Care may include:

  • Airway-clearance techniques to move mucus out of the lungs
  • Inhaled medicines to open the airways or thin mucus
  • Antibiotics for certain infections
  • Treatment for sinus disease
  • Nutritional support or pancreatic enzymes when needed
  • Monitoring for diabetes, liver disease, and bone health
  • Fertility counseling
  • CFTR modulator medicines for eligible variants

CFTR modulators target specific defects in the CFTR protein and can improve its function in people with certain variants. Eligibility depends on the exact genetic findings, age, medical history, and local approvals. A cystic fibrosis center can explain whether these medicines are appropriate.

When should an adult ask about cystic fibrosis?

Consider discussing cystic fibrosis or a CFTR-related disorder with a doctor if you have unexplained bronchiectasis, repeated chest or sinus infections, recurrent pancreatitis, male infertility due to absent sperm, or a close relative with cystic fibrosis. A combination of several milder symptoms can also be meaningful, even if no single symptom seems dramatic.

You may consider a free, online symptom check, using the doctor-approved Ubie Symptom Checker to organize symptoms and questions before an appointment. It cannot diagnose cystic fibrosis or replace medical testing.

Seek urgent medical care for severe breathing difficulty, blue or gray lips, coughing up a large amount of blood, severe chest pain, confusion, or signs of serious dehydration. For anything that could be life-threatening or serious, speak to a doctor or seek emergency care immediately.

An adult diagnosis can be unexpected, but it can also provide an explanation for years of recurring health problems. Confirming the cause allows appropriate monitoring, targeted treatment, and genetic counseling for the individual and their family.

(References)

  • * Read AP. Risk analysis. Methods Mol Med. 1996;5:153-67. doi: 10.1385/0-89603-346-5:153. PMID: 21374516.

  • * Scherdel P, Dunkel L, van Dommelen P, Goulet O, Salaün JF, Brauner R, Heude B, Chalumeau M. Growth monitoring as an early detection tool: a systematic review. Lancet Diabetes Endocrinol. 2016 May;4(5):447-56. doi: 10.1016/S2213-8587(15)00392-7. Epub 2016 Jan 15. PMID: 26777129.

  • * Sathe M, Houwen R. Is meconium ileus associated with worse outcomes in cystic fibrosis? J Cyst Fibros. 2019 Nov;18(6):746. doi: 10.1016/j.jcf.2019.10.003. Epub 2019 Oct 25. PMID: 31668933.

  • * Wright M, Wright T. Health disparity in CF: Perspectives from a lived experience. Pediatr Pulmonol. 2022 Feb;57 Suppl 1:S13-S16. doi: 10.1002/ppul.25727. Epub 2021 Oct 19. PMID: 34647698.

  • * McGarry ME, Ren CL, Wu R, Farrell PM, McColley SA. Detection of disease-causing CFTR variants in state newborn screening programs. Pediatr Pulmonol. 2023 Feb;58(2):465-474. doi: 10.1002/ppul.26209. Epub 2022 Oct 25. PMID: 36237137; PMCID: PMC9870974.

  • * Lin C, Woolfson JP. CFTR:F508d/A613T Mutation Is Associated With Recurrent Episodes of Pancreatitis. JPGN Rep. 2022 Feb;3(1):e142. doi: 10.1097/PG9.0000000000000142. Epub 2021 Nov 29. PMID: 37168745; PMCID: PMC10158408.

  • * Chen JY, Li S, Silva GL, Chandler JD, Prausnitz MR, Guglani L. Sweat induction using Pilocarpine microneedle patches for sweat testing in healthy adults. J Cyst Fibros. 2024 Jan;23(1):112-119. doi: 10.1016/j.jcf.2023.04.014. Epub 2023 May 25. PMID: 37236899.

  • * Martiniano SL, Wu R, Farrell PM, Ren CL, Sontag MK, Elbert A, McColley SA. Late Diagnosis in the Era of Universal Newborn Screening Negatively Affects Short- and Long-Term Growth and Health Outcomes in Infants with Cystic Fibrosis. J Pediatr. 2023 Nov;262:113595. doi: 10.1016/j.jpeds.2023.113595. Epub 2023 Jul 3. PMID: 37406853.

  • * Holý P, Hlaváč V, Šeborová K, Šůsová S, Tesařová T, Rob L, Hruda M, Bouda J, Bartáková A, Mrhalová M, Kopečková K, Al Obeed Allah M, Špaček J, Sedláková I, Souček P, Václavíková R. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression. Int J Cancer. 2024 Jul 1;155(1):104-116. doi: 10.1002/ijc.34908. Epub 2024 Mar 6. PMID: 38447012.

  • * Malmivaara K, Pölkki M, Prami T, Raittinen P, Heikkilä E, Aalto A, Dunder T, Elenius V, Sandström K, McGarry LJ. Cystic fibrosis patient characteristics and healthcare resource utilization in Finland using linked registries. Heliyon. 2024 Jul 15;10(13):e33439. doi: 10.1016/j.heliyon.2024.e33439. Epub 2024 Jun 22. PMID: 39040318; PMCID: PMC11261030.

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.